Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour. The platform is made up of a tumour-targeting agent and a cancer therapeutic, which are activated via ‘click chemistry’. […]
